Versant Capital Management, Inc - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Versant Capital Management, Inc ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q4 2023$2,778
+126.8%
36
+100.0%
0.00%
Q3 2023$1,225
-25.0%
18
-10.0%
0.00%
-100.0%
Q2 2023$1,633
+178.7%
20
+150.0%
0.00%
Q1 2023$586
-11.6%
80.0%0.00%
Q4 2022$663
-33.7%
8
+300.0%
0.00%
Q3 2022$1,0002
+100.0%
0.00%
Q2 2022$010.0%0.00%
Q1 2022$0
-100.0%
10.0%0.00%
Q4 2021$1,00010.0%0.00%
Q3 2021$010.0%0.00%
Q2 2021$010.0%0.00%
Q1 2021$010.0%0.00%
Q4 2020$010.0%0.00%
Q3 2020$010.0%0.00%
Q2 2020$010.0%0.00%
Q1 2020$010.0%0.00%
Q4 2019$010.0%0.00%
Q3 2019$010.0%0.00%
Q2 2019$01
-75.0%
0.00%
Q1 2019$040.0%0.00%
Q4 2018$040.0%0.00%
Q3 2018$040.0%0.00%
Q2 2018$040.0%0.00%
Q1 2018$040.0%0.00%
Q4 2017$040.0%0.00%
Q3 2017$040.0%0.00%
Q2 2017$040.0%0.00%
Q1 2017$040.0%0.00%
Q4 2016$040.0%0.00%
Q3 2016$04
-50.0%
0.00%
Q2 2016$0
-100.0%
8
-33.3%
0.00%
-100.0%
Q1 2016$1,0000.0%120.0%0.00%0.0%
Q4 2015$1,000120.00%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders